CR20230529A - Inhibidores de nlrp3 - Google Patents

Inhibidores de nlrp3

Info

Publication number
CR20230529A
CR20230529A CR20230529A CR20230529A CR20230529A CR 20230529 A CR20230529 A CR 20230529A CR 20230529 A CR20230529 A CR 20230529A CR 20230529 A CR20230529 A CR 20230529A CR 20230529 A CR20230529 A CR 20230529A
Authority
CR
Costa Rica
Prior art keywords
nlrp3 inhibitors
compounds
nlrp3
inhibitors
methods
Prior art date
Application number
CR20230529A
Other languages
English (en)
Inventor
Stefanie Katharina Mesch
Andreas Michael Tosstorff
Lea Aurelie Bouche
Wolfgang Guba
Georg Jaeschke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20230529A publication Critical patent/CR20230529A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a compuestos novedosos que tienen la fórmula general Ib Ib en donde R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> y Z son como se describen en la presente, una composición que incluye los compuestos y métodos para usar los compuestos.
CR20230529A 2021-05-12 2022-05-10 Inhibidores de nlrp3 CR20230529A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21173452 2021-05-12
EP21209447 2021-11-22
EP21215859 2021-12-20
PCT/EP2022/062525 WO2022238347A1 (en) 2021-05-12 2022-05-10 Nlrp3 inhibitors

Publications (1)

Publication Number Publication Date
CR20230529A true CR20230529A (es) 2023-12-04

Family

ID=81941106

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230529A CR20230529A (es) 2021-05-12 2022-05-10 Inhibidores de nlrp3

Country Status (15)

Country Link
US (1) US20240208928A1 (es)
EP (1) EP4337652A1 (es)
JP (1) JP2024517917A (es)
KR (1) KR20240007152A (es)
AR (1) AR125818A1 (es)
AU (1) AU2022275300A1 (es)
BR (1) BR112023023527A2 (es)
CA (1) CA3214626A1 (es)
CO (1) CO2023016204A2 (es)
CR (1) CR20230529A (es)
IL (1) IL307188A (es)
MX (1) MX2023012907A (es)
PE (1) PE20240126A1 (es)
TW (1) TW202311245A (es)
WO (1) WO2022238347A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
WO2023131277A1 (zh) * 2022-01-07 2023-07-13 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
WO2024094185A1 (zh) * 2022-11-04 2024-05-10 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
WO2024121086A1 (en) * 2022-12-07 2024-06-13 F. Hoffmann-La Roche Ag Novel compounds as modulators of nlrp3 inhibition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3

Also Published As

Publication number Publication date
US20240208928A1 (en) 2024-06-27
PE20240126A1 (es) 2024-01-22
MX2023012907A (es) 2023-11-08
CA3214626A1 (en) 2022-11-17
AU2022275300A1 (en) 2023-09-21
TW202311245A (zh) 2023-03-16
AR125818A1 (es) 2023-08-16
EP4337652A1 (en) 2024-03-20
BR112023023527A2 (pt) 2024-01-30
JP2024517917A (ja) 2024-04-23
KR20240007152A (ko) 2024-01-16
CO2023016204A2 (es) 2023-12-11
IL307188A (en) 2023-11-01
WO2022238347A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
CR20230529A (es) Inhibidores de nlrp3
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
CR9244A (es) AMINO-IMIDAZOLONAS PARA LA INHIBICION DE ß-SECRETASA
MX2023002224A (es) Compuestos heterociclicos.
CY1114213T1 (el) Μεθοδοι απομονωσης κρυσταλλικης μορφης ι της 5-αζακυτιδινης
EA200970156A1 (ru) Пиридизиноновые производные
EA200800321A1 (ru) Ингибиторы гистондеацетилазы
MX2013006101A (es) Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos.
EA200601896A1 (ru) Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
AU2020317609A8 (en) Novel heteroaryl-triazole compounds as pesticides
MY169267A (en) New aryl-quinoline derivatives
CR20220116A (es) Compuestos heterocíclicos
CR20220118A (es) Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl)
MX2023013998A (es) Derivados de triazina y su uso en el tratamiento del cancer.
MX2023012477A (es) Compuestos heterociclicos.
CR20220117A (es) Compuestos heterocíclicos
MX2023009045A (es) Derivados novedosos de pirimidin-2-il sulfonamida.
CR20220004A (es) Nuevos compuestos heterocíclicos
WO2018035346A8 (en) KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
MX2022011708A (es) Derivados de benzodiazepinas como moduladores alostericos positivos (pam) de acido gamma-aminobutirico (gaba) a gamma1.
MX2023011014A (es) Inhibidores de heteroarílo de la calicreína plasmática.
TNSN05277A1 (en) Novel bioisosteres of actinonin
MXPA06000936A (es) Derivados de nicotinamida utiles como inhibidores de pde4.